Abstract Body

Background

In vivo reactivation of proviral gene expression without off-target effects may be required for an HIV cure but has remained elusive. We previously designed a latency reversing agent that delivers Tat mRNA to primary CD4+ cells (Ib-Tat mRNA-LNP). Treatment of primary cells with Ib-Tat mRNA-LNP minimally perturbs the host transcriptome and reactivates latent p24 expression as efficiently as a mitogen. Here, we infused Ib-Tat mRNA-LNP into animal models of HIV and assessed for lentiviral transactivation and toxicity.

Methods

Ib-Tat mRNA-LNP were generated via conjugation of ibalizumab (Ib) to the surface of Tat mRNA-lipid nanoparticles (LNP). HIV-infected humanized mice and SHIV-infected macaques were placed on ART and infused with 0.3-1.0 mg/kg Ib-Tat mRNA-LNP 2-8 months later (mice at 1mg/kg: 2 months post-ART; macaques at 0.3mg/kg: 5 months; macaques at 1mg/kg: 8 months). Control animals received nothing or empty Ib-LNP lacking mRNA cargo. Serially sampled blood was assessed for cell associated viral RNA (caRNA), viral DNA, and plasma viral load. caRNA:DNA ratio was calculated as a measure of lentiviral transcriptional activity.

Results

80% of humanized mice (8/10) and 100% of rhesus macaques (9/9) achieved viral load suppression. 4/4 suppressed humanized mice and 3/6 suppressed macaques treated with Ib-Tat mRNA-LNP experienced on-ART viremia following infusion, whereas no control animals did (0/4 and 0/3, respectively). On-ART viremia differed between model organisms, with humanized mice demonstrating 1,000-50,000 copies/ml and macaques demonstrating 15-241 copies/ml. In the 72 hours following infusion, all Ib-Tat mRNA-LNP treated monkeys exhibited elevated caRNA as compared to vehicle control monkeys (AUC caRNA vs. time, geomean 18,090 vs. 850, p= 0.0238). This corresponded to an elevated caRNA:DNA ratio, with greatest response seen in the 1mg/kg group (caRNA:DNA vs. time AUC for untreated macaques: 17.4; vehicle treated: 125.3, 0.3 mg/kg treated: 222.9; and 1.0 mg/kg treated: 18,444.8). We observed mild-to-moderate aminotransferase elevation in treated macaques (peak AST: 69-149; peak ALT:55-102) that normalized within 72 hours.

Conclusions

We report, to our knowledge, the first instance of in vivo latency reversal using targeted mRNA gene therapy, which resulted in on-ART viremia in a subset of animals. This intervention, which was well tolerated and composed of materials akin to other targeted mRNA therapeutics in human testing, is primed for use in future HIV cure strategies.